Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$456.04 USD
+6.48 (1.44%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $456.04 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALNY 456.04 +6.48(1.44%)
Will ALNY be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for ALNY
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
Other News for ALNY
Bullish Engulfing appears for ALNY after 1.44% move
Alnylam Pharmaceuticals Launches Promising Phase 3 Study on Nucresiran for hATTR-PN
ALNY: Piper Sandler Raises Price Target Amid Overweight Rating | ALNY Stock News
Barclays Raises Price Target for Alnylam Pharmaceuticals (ALNY) to $527 | ALNY Stock News
Evercore ISI Sticks to Their Buy Rating for Alnylam Pharma (ALNY)